Cellectis CLLS 深 滬
等待開盤 12-13 09:30:00 美东时间
4.79
-0.430
-8.24%
華盛通- 最 高5.05
- 今 開5.05
- 成交量 10.20万股
- 最 低 4.75
- 昨 收 5.22
- 總市值 4.79亿
- 52周最高 5.4796
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 1.10
- 委 比 81.82%
- 總股本 10000.00万
- 歷史最高 50.00
- 量 比 2.79
- 振 幅 5.75%
- 歷史最低 0.9628
- 每 手 1
- 風險率 1.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Cellectis presented encouraging updated data from its Phase 1 NATHALI-01 trial for eti-cel, an allogeneic dual CAR-T therapy targeting CD20 and CD22. In patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL) following ≥2 prior therapies, eti-cel achieved an 88% overall response rate (ORR) and 63% complete response (CR) at the current dose level. Preclinical data suggest that low-dose IL-2 administration may enhance CAR-T cell expansion ...
12-08 06:30
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
The latest announcement is out from Cellectis SA ( ($CLLS) ). On December 5, 20...
12-06 05:28
Monthly information on share capital and company voting rights
On November 30, 2025, Cellectis reported a total of 100,325,454 shares and 105,406,812 voting rights. For further details, contact Pascalyne Wilson via media@cellectis.com or Arthur Stril via investors@cellectis.com.
12-03 21:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Inspire Veterinary (NASDAQ:IVP) stock increased by 77.5% to $0.22 duri...
11-24 20:05
Why Cellectis Stock Is Trading Higher Today
Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.
11-20 03:12
Cellectis Boosts Gene Editing Efficiency With New Non-Viral DNA Breakthrough in Stem Cells
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature
11-19 19:20
Cellectis shares are trading higher after the company reported better-than-expected Q3 financial results.
Cellectis shares are trading higher after the company reported better-than-expe...
11-10 22:28
Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.28) by 107.19 percent. This is a 109.09 percent increase over losses of $(0.22) per share from the
11-08 05:32
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11
Monthly information on share capital and company voting rights
On October 31, 2025, Cellectis reported a total of 100,325,454 shares and 89,406,760 voting rights. The announcement, listed on Euronext Growth under ISIN FR0010425595, includes contact information for media and investors. For more details, refer to the attached document "Voting_Rights_PR_October_2025_EN."
11-07 16:30
